Jazz Pharmaceuticals JAZZ Accumulated Depreciation
Accumulated Depreciation at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's accumulated depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's accumulated depreciation?
- Jazz Pharmaceuticals (JAZZ) reported accumulated depreciation of $181.7M in Q1 2026.
- How has Jazz Pharmaceuticals's accumulated depreciation changed year-over-year?
- Jazz Pharmaceuticals's accumulated depreciation increased by 5.9% year-over-year, from $171.56M to $181.7M.
- What is the long-term trend for Jazz Pharmaceuticals's accumulated depreciation?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's accumulated depreciation has grown at a 21.4% compound annual growth rate (CAGR), from $67.59M to $178.5M.